AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Nykode Therapeutics ASA

Director's Dealing • Nov 24, 2025

3695_dirs_2025-11-24_3dcde523-0c47-4705-97f9-0b647f59a496.html

Director's Dealing

Open in Viewer

Opens in native device viewer

Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider

Oslo, Norway, November 24, 2025 - Primary insider Michael Engsig, Chief Executive Officer of Nykode Therapeutics ASA, has today acquired 46,356 shares in Nykode Therapeutics ASA at a price of NOK 2.16 per share. Following the transaction, Michael Engsig holds 118,150 shares in Nykode Therapeutics ASA.

Please see further details in the attached document.

Talk to a Data Expert

Have a question? We'll get back to you promptly.